Regeneron Pharmaceuticals

Open: 877.91 Close: 878.29 Change: 0.38

Our AI found unexpected things about Regeneron Pharmaceuticals Company Inc.

This document will help you to evaluate Regeneron Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, Pharmaceuticals, stock, price, drug, biotech, Inc, …

Concept Map

Semantic Network

Stock Summary

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. The company's products include EYLEA injection to treat neovascular age-related macular degeneration.

Today's Summary

Regeneron Pharmaceuticals Inc. stock underperforms friday when compared to competitors. The superstar eye drug pulled $1.49 billion in 2023s third quarter, including $43 million from its high-dose counterpart, and has been a major blockbuster drug.

Today's News

Regeneron Pharmaceuticals Inc. stock underperforms friday when compared to competitors - marketwatch.comwatch.org. The superstar eye drug pulled $1.49 billion in 2023s third quarter, including $43 million from its high-dose counterpart, and has been a major blockbuster drug for Regeneron. Regeneron Pharmaceuticals (REGN) has on average historically risen by 32.3% based on the past 32 years of stock performance. The current share price is $877.80 USD today. Regeneron Pharmaceuticals stock price is 0.44% down from $877.91 opening price on Friday 12/29/2023 on BTT. New: Online Broker Comparison. Regeneron Pharmaceuticals is a biotech company focused on developing therapies to treat metabolic disorders, inflammatory diseases, cancer and respiratory conditions. The biotech firm edged less than 1% higher, adding to Wednesdays gains.

Stock Profile

"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York."

Keywords

Are looking for the most relevant information about Regeneron Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Regeneron Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, Pharmaceuticals, stock, price, drug, biotech, Inc, and the most common words in the summary are: regeneron, pharmaceutical, stock, market, inc, company, news, . One of the sentences in the summary was: Regeneron Pharmaceuticals Inc. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #regeneron #pharmaceutical #stock #market #inc #company #news.